Generated by AI
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.
Website9704 Medical Center Drive
Rockville, MD, 20850
United States
The latest articles about MGNX.
Summary of Oct 26's posts. Generated by AI.
Summary of May 12's posts. Generated by AI.
Summary of May 12's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Investors talking about MGNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.